The sodium iodide symporter (NIS) is a novel autoantigen in autoimmune thyroid disease (ATD). A recent study has described the development of a bioassay for human (h) NIS antibody detection, but this will not detect antibodies that bind the symporter without modulating its activity. Therefore, the establishment of a binding assay is of importance to determine the overall prevalence of hNIS antibodies in ATD patients. An in vitro transcription and translation system was used to produce [ 35 S]-labeled hNIS. The radiolabeled ligand reacted specifically in immunoprecipitation experiments with rabbit antiserum raised against a peptide fragment of hNIS. Subsequently, the reactivity of control and ATD sera to translated [ 35 S]hNIS was determined using RIAs.
S]-labeled hNIS. The radiolabeled ligand reacted specifically in immunoprecipitation experiments with rabbit antiserum raised against a peptide fragment of hNIS. Subsequently, the reactivity of control and ATD sera to translated [ 35 S]hNIS was determined using RIAs.
A significant difference in the frequency of hNIS antibody-positive sera was found when patients with either Graves' disease (GD) or autoimmune hypothyroidism (AH) were compared with normal controls (P ϭ 0.01 and P ϭ 0.03, respectively). Of 49 GD and 29 AH sera tested, 11 (22%) and 7 (24%), respectively, were found to contain hNIS antibodies. Differences were also significant when the antibody-binding indices of the control group of sera were compared with those of both the GD and the AH patient sera (P Ͻ 0.0001 and P ϭ 0.001, respectively). In contrast, sera from 10 patients with Addison's disease and 10 patients with vitiligo (without associated ATD) were all negative for antibody reactivity to the symporter. No differences were detected when the antibody binding indices of either the Addison's disease or the vitiligo sera were compared with those of the normal sera group (P ϭ 0.9 and P ϭ 0.6, respectively).
Eight of the 11 (73%) GD and 3 of the 7 (43%) AH sera, which were positive for hNIS antibodies in the immunoprecipitation assay, were also found to inhibit iodide uptake in hNIS-transfected CHO-K1 cells, suggesting the existence of antibodies in some serum samples that bind to the symporter without modulating its function. Overall, a significant correlation was found between the iodide uptake inhibition and the binding assays for hNIS antibody detection (r ϭ 0.49, P Ͻ 0.0001).
In summary, we have developed a specific and quantitative assay for the detection of hNIS binding antibodies in sera of patients with ATD. This system offers the advantage of studying antibody reactivity against conformational epitopes and will be useful in understanding the role of NIS autoreactivity in the pathogenesis of ATD. (J Clin Endocrinol Metab 85: 2020 -2027, 2000) S EVERAL PIECES of evidence indicate that the sodium iodide symporter (NIS) is a novel autoantigen in autoimmune thyroid disease (ATD) (1) . Early suspicion of this came from the work of Raspé et al. (2) , who demonstrated that serum from a single patient with Hashimoto's thyroiditis (HT), of 147 sera studied, inhibited iodide uptake in dog thyrocyte culture. However, there was no proof that the inhibitory activity of this serum was antibody-mediated. After cloning of the rat (r) symporter (3), more refined studies have been conducted to investigate the presence of NIS antibodies. Sera from ATD patients, in particular Graves' disease (GD), have been shown to bind the recombinant rNIS expressed in a bacterial system (4) . Furthermore, the majority of GD and a minority of HT sera displayed an increased reactivity against a number of rNIS peptides in an enzymelinked immunosorbant assay (5) . It has been shown also that HT IgGs, which bind the recombinant rNIS, can inhibit symporter activity (6) , which may have important clinical implications. Most studies have focused on the rNIS, although the activity of autoantibodies can be species-specific (7) . Indeed, a recent study has shown that GD sera reactivity against human (h) NIS peptides is not different from that of controls (8) , emphasizing the potential problems of analyzing antibody reactivity using xenogenic antigens.
We have developed a bioassay that demonstrated that 30% of GD sera can modulate hNIS activity, an effect that was antibody-mediated (9) . Although the bioassay is suitable for the investigation of conformational epitopes, it cannot detect antibodies that bind the hNIS without modulating its function. Taken together, the production of the hNIS in its native form (or at least a form close to it), suitable for application in a binding assay, seems necessary for the proper evaluation of autoantibodies against the symporter.
A common problem encountered in the study of autoantibody reactivity is the lack of pure uncontaminated antigen, often resulting in a background of nonspecific antibody reactivity, in turn making interpretation of the results difficult. Recently, autoantigens have been produced in an in vitro transcription and translation (TnT) system that offers the advantage of investigating antibody reactivity against a single protein (10 -15) , rendering assays highly specific and sensitive.
In the present work, we describe the in vitro production of [ 35 S]-labeled hNIS and the immunoprecipitation of the translated antigen by antibodies in sera from patients with ATD. We also demonstrate the presence of antibodies that bind to but do not block the activity of the symporter, thus extending the profile of autoreactivity to this novel autoantigen.
Materials and Methods Patients
Sera from 49 GD (8 men, 41 women; mean age, 49 yr; age range, 23-80 yr) and 29 autoimmune hypothyroidism (AH) (4 men, 25 women; mean age, 51 yr; age range, 28 -81 yr) patients were used in this study. Diagnosis of GD was based on the presence of hyperthyroidism, supported by one or more of the following features: a diffuse goiter, the presence of thyroglobulin or thyroid peroxidase antibodies, and evidence for thyroid-associated ophthalmopathy. AH was diagnosed by the presence of hypothyroidism and positive thyroglobulin or thyroid peroxidase antibodies. Of the 49 GD patients studied, 25 were newly diagnosed untreated GD patients and 12 had associated ophthalmopathy (grade II-IV), of whom 4 had also pretibial myxedema. Sera were also obtained from 10 patients with isolated vitiligo and 10 with Addison's disease (AD), without any evidence of associated ATD. Sera from 20 normal individuals (9 men, 11 women; mean age, 31 yr; age range, 23-47 yr) were used as controls. Patient and control IgGs were prepared as described elsewhere (9) .
The study was approved by the Ethics Committee of the Northern General Hospital, Sheffield, and all subjects gave informed consent. All sera were kept frozen at Ϫ20 C before analysis.
Antisera
Rabbit antiserum against a hNIS fragment (amino acids 466 -522) has been described previously (16) and was used as a positive control. Antityrosinase rabbit antiserum ␣PEP7, which was used as a negative control, was a gift of Prof. V. Hearing (NIH, Bethesda, MD; Ref. 17) .
hNIS complementary DNA (cDNA) constructs
The full-length hNIS cDNA and a truncated version encoding amino acids (aa) 1-643 and 1-612 of hNIS, respectively, both cloned into the eukaryotic expression vector pcDNA3, were a gift from Dr. S. M. Jhiang (The Ohio State University, Columbus, OH; Ref. 18 ). The plasmids were prepared from Escherichia coli JM109 (Promega Corp., Southampton, UK) using a Wizard Maxipreps DNA Purification System (Promega Corp.), according to the manufacturer's protocol.
Iodide uptake and iodide uptake inhibition studies
A stable CHO-K1 cell line containing full-length hNIS and designated CHO-NIS12 was established using steps identical to those used in the isolation of CHO-NIS9, which contains truncated (aa 1-612) hNIS (9) . The cell line was subsequently tested for iodide uptake activity, as detailed elsewhere (9) . Briefly, hNIS-transfected CHO-K1 cells were cultured in 6-well plates, and iodide uptake was analyzed when these cells reached 100% confluence. Untransfected CHO-K1 cells were used as a control.
125 I (17 Ci/mg; NEN Life Science Products, Hounslow, UK), 1.5-2 kBq, was incubated with the cells in 1 mL serum-free Ham's F-12 medium (Life Technologies, Inc., Paisley, UK) for 30 min. Cells were then washed quickly with phosphate-buffered saline (PBS), solubilized with 1 mL of 1 mol/L NaOH, and radioactivity was counted in a Wallac, Inc. 1282 Compugamma counter (Wallac UK, Milton Keynes, UK). For untransfected cells, iodide uptake in cpm was assigned a value of 1. For CHO-NIS9 and CHO-NIS12, iodide uptake was expressed as: iodide uptake in cpm in transfected cells/iodide uptake in cpm in untransfected cells. The mean of duplicate cultures Ϯ sem was calculated and used to express the results.
The effect of perchlorate on the iodide uptake activity of both CHO-NIS9 and CHO-NIS12 was assessed by incubating the cells with 1 mmol/L perchlorate before the addition of 125 I. Again, untransfected cells were used as a control. For perchlorate-treated untransfected cells, iodide uptake in cpm was assigned a value of 1. For perchlorate-treated transfected cells, iodide uptake was expressed as: iodide uptake in cpm in perchlorate-treated transfected cells/iodide uptake in cpm in perchlorate-treated untransfected cells. The mean of duplicate cultures Ϯ sem was calculated and used to express the results.
To determine the effects of control and ATD patient sera on symporter activity, either 100 L serum or 2 mg/mL IgG in 1 mL serum-free medium were incubated with hNIS-transfected CHO-K1 cells at 37 C for 60 min. An additional 1 mL medium containing 3-4 kBq of 125 I was added, and the cells were incubated for an additional 30 min, followed by washing, solubilization, and counting as above. Each serum/IgG was tested twice, and results expressed as the mean percentage of inhibition of iodide uptake by hNIS-transfected CHO-K1 cells. The mean Ϯ sem intra-and interassay coefficients of variation for the bioassay, obtained by testing 10 serum samples on three occasions, were 5.3 Ϯ 0.9% and 6.7 Ϯ 1.4%, respectively.
Rubidium uptake and rubidium uptake inhibition studies
CHO-NIS9 cells were cultured in 6-well plates, and 86 Rb uptake was analyzed when these cells reached 100% confluence. Untransfected CHO-K1 cells were used as a control.
86 Rb (Ͼ1Ci/g; NEN Life Science Products), 2 kBq, was incubated with the cells in 500 L serum-free medium for 30 min. Cells were then washed quickly with PBS and solubilized with 200 L of 1 mol/L NaOH. Scintillation fluid was added to 100 L solubilized cells, and radioactivity was counted in a Compugamma counter.
To determine the effects of control and ATD patient sera on the activity of the Na ϩ /K ϩ ATPase, hNIS-transfected CHO-K1 cells were incubated with either 50 L serum or 2 mg/mL IgG in 500 L serum-free medium. After 60 min of incubation at 37 C, 500 L medium containing 4 kBq of 86 Rb were added to the cells, and incubation continued for an additional 30 min. Cells were then washed, solubilized, and counted as above. Each serum/IgG was tested twice, and results were expressed as the mean percentage of inhibition of rubidium uptake by hNIS-transfected CHO-K1 cells.
In vitro-coupled TnT of hNIS
The full-length hNIS protein was produced in vitro from its cDNA using a TnT T7 Coupled Reticulocyte Lysate System (Promega Corp.). 35 S]hNIS was achieved using N-Glycosidase F (Roche Molecular Biochemicals, Lewes, UK), as detailed by the supplier's instructions. In brief, an aliquot of the glycosylated [
35 S]hNIS was incubated at 37 C for 12 h with 2 U enzyme in buffer containing 100 mmol/L sodium phosphate buffer (pH 6.5), 10 mmol/L EDTA, 0.1% SDS, and 0.5% Triton X-100. 35 S]hNIS were added to SDS-sample buffer containing 63 mmol/L Tris-HCl (pH 6.8), 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.001% bromophenol blue and heated to 100 C for 2 min before loading onto a gel. To visualize protein markers, the gel was stained with 0.05% Coomassie blue in 10% glacial acetic acid/ 25% isopropanol and destained with 10% glacial acetic acid/25% isopropanol each for 30 min at room temperature. The gel was then soaked in Amplify scintillant (Amersham Pharmacia Biotech) for 30 min at room temperature before drying at 80 C for 2 h onto 3MM chromatography paper (Whatman International Ltd., Maidstone, UK) under vacuum. Autoradiography was carried out at Ϫ70 C using x-ray film (Genetic Research Instrumentation Ltd., Dunmow, UK). Protein molecular weight standards (Sigma, Dorset, UK) consisted of myosin (205 kDa), ␤-galactosidase (116 kDa), phosphorylase b (97 kDa), serum albumin (66 kDa), ovalbumin (45 kDa), and carbonic anhydrase (29 kDa).
Electrophoretic analysis and autoradiography

SDS-PAGE (19) of in vitro-
Immunoprecipitation of [ 35 S]-labeled hNIS
For each assay, an aliquot of the in vitro translation reaction mixture (equivalent to 20,000 cpm of trichloroacetic acid precipitable material) was suspended in 50 L immunoprecipitation buffer containing 20 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% Triton X-100, and 10 g/mL aprotinin (Bayer Corp., Newbury, UK). The serum to be analyzed was then added to a final dilution of 1:10, unless otherwise specified. After incubation overnight with shaking at 4 C, 50 L protein G Sepharose 4 Fast Flow slurry (Pharmacia Biotech, Uppsala, Sweden), prepared according to the manufacturer's protocol, was added and incubated for 1 h at 4 C. The protein G Sepharose-antibody complexes were then collected by centrifugation and washed six times for 15 min in immunoprecipitation buffer at 4 C. Immunoprecipitated radioactivity in cpm was evaluated in a LKB 1217 Rackbeta liquid scintillation analyzer (Wallac, UK).
Antibody binding was expressed as an immunoprecipitation index (hNISAb index) defined as: the cpm immunoprecipitated by each tested sample/the mean cpm immunoprecipitated by 20 normal controls. Each serum sample was assayed at least three times, and a mean hNISAb index was calculated. The mean Ϯ sem intra-and interassay coefficients of variation for the binding assay, obtained by testing five samples on three occasions, were 12.1 Ϯ 1.6% and 14.8 Ϯ 1.7%, respectively.
For analysis by SDS-PAGE, the protein G Sepharose-antibody complexes were resuspended in 100 L SDS-sample buffer, boiled, and centrifuged and the supernatant was recovered for electrophoresis.
For dilution experiments, hNIS antibody-positive sera were analyzed in the immunoprecipitation assay at dilutions of 1:10, 1:50, 1:100, and 1:200. Specific anti-hNIS rabbit antiserum was tested in the assay at dilutions of 1:10, 1:50, 1:100, 1:200, 1:500, 1:1000, and 1:2000.
Absorption studies
For preparation of extracts, both CHO-K1 or CHO-NIS12 cells were scraped on ice from the surface of tissue culture dishes. After washing in PBS, 1 mL immunoprecipitation buffer containing 10 g/mL aprotinin (Bayer Corp.), 100 mol/L N␣-tosyl-phenylalanylchloromethyl ketone (Novobiochem, Nottingham, UK), 100 mol/L N␣-tosyl-lysyl chloromethyl ketone (Sigma, Poole, UK), and 10 mol/L pepstatin A (Novobiochem) were added, and cells were lysed by two freeze thaw cycles. The resulting lysate was sonicated on ice for six bursts of 6 sec each. Unlysed cells were then removed by centrifugation at 7000 ϫ g. The total amount of protein in cell extracts was determined by the method of Bradford (20) .
Serum samples from a pool of 20 normal controls and from three ATD patients positive for hNIS antibodies were preincubated in immunoprecipitation buffer with CHO-K1 or CHO-NIS12 cell extracts, both containing equal amounts of total protein. After a 12-h incubation at 4 C, in vitro-translated [ 35 S]hNIS was added and immunoprecipitation was carried out as described previously. For each serum, the results are expressed as: the mean cpm immunoprecipitated in three experiments as a percentage of the mean cpm immunoprecipitated in three experiments without preincubation with extract.
Immunoprecipitation assay for Pmel17 autoantibodies
Pmel17 antibody reactivity was determined by immunoprecipitation of [
35 S]-labeled Pmel17, as described previously (21) . Pmel17-specific rabbit antiserum and Pmel17 cDNA are detailed elsewhere (21) .
Statistical analysis
Differences in immunoprecipitation indices of the different groups were analyzed using Mann-Whitney tests. Differences in the frequency of iodide uptake inhibitory activity of GD and AH sera compared with controls were further tested using 2 ϫ 2 contingency tables. Correlation was analyzed using Pearson's correlation test.
Results
Iodide uptake and uptake inhibition studies
To establish a stable cell line, CHO-K1 cells were transfected with full-length hNIS and a total of 24 colonies were picked for further analysis. Six colonies displayed 125 I uptake activity ranging from a 10-to 60-fold increase above untransfected cells. One clone designated CHO-NIS12 was selected for additional studies, with an iodide uptake activity that was 5-fold higher than our previous stable cell line CHO-NIS9, which expressed a truncated (aa 1-612) form of the symporter (Fig. 1) . It is not known whether this increased activity is due to differences in the level of expression of the symporter or whether it relates to a specific functional role of the last 31 amino acids of the protein. The iodide uptake activity of both CHO-NIS9 and CHO-NIS12 was completely abolished by incubating the cells with 1 mmol/L perchlorate (Fig. 1) . Sera, from 49 GD patients and 31 controls, had been tested previously for iodide uptake inhibitory activity using CHO-NIS9 (9). In addition, 29 sera from AH patients had been analyzed for inhibiting hNIS function in the same cell line (22) . A mean inhibition of iodide uptake of 17% was determined for the group of control sera (9) . Any patient serum with an inhibition activity of more than 30% (the mean percentage of inhibition of iodide uptake of 31 control sera ϩ 3 sd) was regarded as positive ( Fig. 2A; Ref. 9 ). On this basis, 16 GD (33%) and 6 (21%) AH patient sera were positive for inhibition activity (Table 1) . Because a truncated form of the symporter was used in this bioassay, some inhibitory positive samples may have been missed if a critical epitope is situated at the carboxy-terminal of the molecule. Therefore, 18 (11 GD and 7 AH) sera were also tested using the new cell line CHO-NIS12, which expressed the fulllength hNIS. No additional positive samples could be detected, suggesting that the CHO-NIS9 cells were sufficient for the investigation of antibodies that modulate the hNIS function. Furthermore, a highly significant correlation was detected between the two cell lines by testing 10 different sera (r ϭ 0.92, P Ͻ 0.0001), indicating the validity of our previous results using the truncated form of the hNIS.
Six IgG samples from two normals, two AH patients, and two GD patients were tested for their effect on iodide uptake by CHO-NIS9 cells. The AH and GD samples were selected because the sera contained hNIS inhibitory activity. A mean percentage (Ϯ sem) inhibition of iodide uptake of 1.8 (Ϯ 2.2) was determined for the group of control IgGs. Any patient IgG with an inhibition activity of more than 10.8% (the mean percentage of inhibition of iodide uptake of two control sera ϩ 3 sd) was, therefore, regarded as positive. With respect to   FIG. 2 . A, The effect of ATD and control sera on the uptake of either iodide or rubidium in CHO-NIS9 cells. Iodide and rubidium uptake inhibition by sera were measured as described in Materials and Methods. Results are shown for six normal (N) controls, three AH, and three GD sera. Each serum was tested twice, and the results are expressed as the mean percentage Ϯ SEM of inhibition of either iodide or rubidium uptake by CHO-NIS9 cells. The dotted line at 30% represents the upper limit of normal for iodide uptake inhibition calculated as: the mean percentage of inhibition of iodide uptake of 31 control sera ϩ 3 SD. The dotted line at 22% represents the upper limit of normal for rubidium uptake inhibition calculated as: the mean percentage of inhibition of rubidium uptake of six control sera ϩ 3 SD. B, The effect of ATD and control IgGs on the uptake of either iodide or rubidium in CHO-NIS9 cells. Iodide and rubidium uptake inhibition by IgGs was measured as described in Materials and Methods. Results are shown for two normal (N) controls, two AH, and two GD sera. Each IgG was tested twice, and the results are expressed as the mean percentage Ϯ SEM of inhibition of either iodide or rubidium uptake by CHO-NIS9 cells. The dotted line at 10.8% represents the upper limit of normal for iodide uptake inhibition calculated as: the mean inhibition of iodide uptake of two control sera ϩ 3 SD. The dotted line at 9.7% represents the upper limit of normal for rubidium uptake inhibition calculated as: the mean inhibition of rubidium uptake of two control sera ϩ 3 SD. this, all four patient IgG samples analyzed were positive for iodide uptake inhibition activity (Fig. 2B) .
Rubidium uptake and rubidium uptake inhibition studies
Sera (three GD patients, three AH patients, and six controls), which had been tested for iodide uptake inhibitory activity using CHO-NIS9, were analyzed for their effect on the uptake of 86 Rb in the same cell line. The AH and GD serum samples chosen contained hNIS inhibitory activity. A mean percentage (Ϯ sem) inhibition of 86 Rb uptake of 4.3 (Ϯ2.4) was determined for the group of control sera. Patient sera with an inhibition activity of more than 22% (the mean percentage of inhibition of rubidium uptake of six control sera ϩ 3 sd) were regarded as positive. On this basis, none of the patient sera examined was positive for inhibition of Na ϩ /K ϩ ATPase activity ( Fig. 2A) . Six IgG samples from two normals, two AH patients, and two GD patients were tested for their effect on rubidium uptake by CHO-NIS9 cells. The AH and GD samples were selected because the sera contained iodide uptake inhibitory activity. A mean percentage (Ϯsem) inhibition of 86 Rb uptake of 2.8 (Ϯ1.7) was determined for the control IgGs. Any patient IgG with an inhibition activity of more than 9.7% (the mean percentage of inhibition of rubidium uptake of two control sera ϩ 3 sd) was regarded as positive. With respect to this, all four patient IgG samples tested were negative for rubidium uptake inhibition activity (Fig. 2B) .
Production of hNIS in a TnT system
In vitro-translated [ 35 S]-labeled hNIS was analyzed by SDS-PAGE and autoradiography, revealing a protein product of 60 kDa (Fig. 3) , which is similar in size to that described for unglycosylated hNIS in human thyrocytes (16) . On addition of Canine Microsomal Membranes to the translation reaction, a band of 66 kDa was detected, which we assumed to represent the glycosylated form of [ 35 S]hNIS (Fig. 3) . This increase in molecular weight of hNIS could be specifically reversed by adding the deglycosylating enzyme N-Glycosidase F to the reaction containing glycosylated protein (Fig. 3) .
Immunoprecipitation of [ 35 S]-labeled unglycosylated hNIS
The immunoreactivity of the in vitro-translated recombinant [
35 S]hNIS was tested using rabbit antisera at a 1:10 dilution; [ 35 S]hNIS was immunoprecipitated by anti-hNIS antiserum but not by antityrosinase antiserum ␣PEP7 (Fig. 4) .
To establish a reference range of hNISAb indices, sera from 20 healthy controls were tested for their ability to immunoprecipitate [
35 S]hNIS. Any patient serum that had an hNISAb index above 2.0 (the mean hNISAb index of 20 control sera ϩ 3 sd) was regarded as positive. On this basis, 11 of 49 (22%) GD and 7 of 29 (24%) AH sera were positive in this binding assay (Table 1) , whereas none of the AD or vitiligo samples was positive (Fig. 5 ). Further analysis of GD subgroups showed that 6 of the 25 (24%) untreated sera and 3 of 16 (19%) of those with extrathyroidal complications were positive.
The mean immunoprecipitation index Ϯ sem of the control, GD, AH, AD and vitiligo groups was: 1.00 Ϯ 0.06, 1.67 Ϯ 0.13, 1.67 Ϯ 0.18, 0.99 Ϯ 0.08, and 1.09 Ϯ 0.12, respectively. A significant difference was detected when immunoprecipi- 
FIG. 4. SDS-PAGE and autoradiography of [
35 S]hNIS immunoprecipitated with anti-hNIS rabbit antiserum (positive control) and antityrosinase rabbit antiserum (negative control), as well as with serum from patients with GD and AH. The positive and negative control antisera, individual ATD patient sera, and a pool of 20 normal control sera were incubated at a dilution of 1:10 with an aliquot of the in vitro translation reaction mixture before incubation with protein G Sepharose, as described in Materials and Methods. The protein G Sepharose-antibody complexes were resuspended in 100 L SDS-sample buffer and boiled, and the supernatant was recovered for analysis by SDS-PAGE and autoradiography. tation indices of control sera were compared with those of GD or AH sera (P Ͻ 0.0001 and P ϭ 0.001, respectively). Differences were also evident comparing ATD with AD or vitiligo sera (P ϭ 0.001 and P ϭ 0.01, respectively), whereas no differences were found comparing AD or vitiligo sera with control sera (P ϭ 0.9 and P ϭ 0.6, respectively). We also failed to detect significant differences between the GD and the AH group (P ϭ 0.6). A significant difference in the frequency of hNIS antibody-positive sera was found when GD and AH patients were compared with normal controls ( 2 ϭ 6.2, P ϭ 0.01 and 2 ϭ 4.5, P ϭ 0.03, respectively). SDS-PAGE was used to check that the radioactivity immunoprecipitated by each of the positive sera was due to [ 35 S]hNIS (Fig. 4) . Positive sera immunoprecipitated a band of the correct size when compared with that precipitated by hNIS-specific rabbit antiserum used as a positive control.
Dilution experiments showed that the reactivity of hNIS antibody-positive sera was clearly evident with dilutions of up to 50-fold. The reactivity of the positive control anti-hNIS rabbit antiserum was detected with dilutions of up to 1000-fold.
Immunoprecipitation of [ 35 S]-labeled glycosylated hNIS
We analyzed antibody binding to in vitro-translated [ 35 S]-labeled glycosylated hNIS. Using 20 normal control sera, a reference range of hNISAb indices was established, as described previously. Fourteen GD and 10 AH sera were tested, including 12 (10 GD and 2 AH) samples that were positive in the bioassay. One of the GD sera that failed to bind un- 
Correlation between the bioassay and the binding assay for the detection of hNIS antibodies
The results of the bioassay and the binding assay for GD and AH sera are summarized in Table 1 . A significant correlation (r ϭ 0.49, P Ͻ 0.0001) was found between the bioassay and the binding assay for hNIS antibody detection (Fig. 6) .
Absorption studies
Cell extracts from CHO-NIS12 cells were used to preabsorb antibody reactivity against the symporter, with extracts from untransfected CHO-K1 cells being used as a control. Fig. 7 shows the results of absorption studies on a pool of 20 normal controls and three ATD sera. Antibody reactivity of the three hNIS antibody-positive sera was reduced by 20 -35% when preabsorbed with CHO-NIS12 extracts. Preincubation with CHO-K1 extracts decreased antibody binding of the patient sera by 0 -10%, indicating some nonspecific absorption of antibody reactivity.
Immunoprecipitation assay for Pmel17 autoantibodies
Sera were examined for antibodies to the melanocyte-specific protein Pmel17 to test the possibility that antibody binding to [ 35 S]hNIS occurred due to nonspecific interactions with radiolabeled ligands. Ten GD, seven AH, eight control sera, and a Pmel17-specific rabbit antiserum (21) were analyzed for Pmel17 antibodies by immunoprecipitation (21) . The patient sera selected were positive for hNIS reactivity in the immunoprecipitation assay. Antibodies to the melanocyte-specific protein Pmel17 were not detected in any of the patient sera. The mean immunoprecipitation index Ϯ sem of the Pmel17-specific rabbit antiserum, control, GD, and AH groups was: 3.63 Ϯ 0.73, 1.00 Ϯ 0.08, 1.01 Ϯ 0.06, and 1.10 Ϯ 0.10, respectively. No significant differences were found when comparing the immunoprecipi- tation indices of control sera with those of either GD or AH sera (P ϭ 0.8 and P ϭ 0.3, respectively).
Discussion
Using labeled proteins produced in a TnT system offers the advantage of studying antibody reactivity against specific antigens, without the need to express and purify the protein of interest in bacterial or mammalian cells. It also allows quantitative measurement of the levels of antibodies together with the possibility of detecting conformational epitopes.
The molecular weight of the [ 35 S]-labeled full-length hNIS was similar to that described for the full-length unglycosylated hNIS in thyroid cells (16) at 60 kDa. However, glycosylation of the symporter in the TnT system resulted in a 66-kDa molecule, which is smaller than the 77 kDa documented for the mature glycosylated hNIS in thyroid cells (16) . This discrepancy in relative molecular weight may be due to less extensive glycosylation of the translated polypeptide or may be due to altered migration of the protein in SDS-PAGE with differing experimental conditions. The translated [
35 S]hNIS was immunoreactive and could be immunoprecipitated by specific anti-hNIS rabbit antiserum, but not by nonspecific antityrosinase rabbit antiserum, further confirming the identity of the translated and labeled material.
Overall, 22% (11 of 49) of GD and 24% (7 of 29) of AH sera reacted with the in vitro-translated unglycosylated [
35 S]hNIS, whereas AD, vitiligo (without associated ATD), or control sera showed no reactivity, indicating a high disease-associated specificity. Glycosylation of the [ 35 S]hNIS had only a minor effect on increasing the sensitivity of the assay. Similar findings have been documented for the thyroid antigens thyroglobulin and thyroid peroxidase, as deglycosylation of these molecules had no effect on autoantibody binding (23) . Interestingly, one sample that reacted with the unglycosylated [
35 S]hNIS, failed to show binding to the glycosylated symporter, suggesting that glycosylation can disrupt antibody binding sites in some cases.
Of the 11 GD sera positive in the hNIS binding assay, 8 (73%) were found to inhibit iodide uptake in hNIS-transfected CHO-K1 cells. This suggests the presence of hNIS antibodies in three samples that bind the symporter without modulating its function. With respect to the AH patient samples, three of the seven (43%) sera positive in the hNIS binding assay also inhibited iodide uptake in the bioassay, again suggesting that four of the sera contained hNIS antibodies that bind to the symporter but fail to affect its activity. However, because the truncated form of the hNIS (aa 1-612) was used in the bioassay, antibodies reacting with epitopes situated at the C-terminal end of the molecule may have missed. Further experiments on a CHO-K1 cell line expressing the full-length hNIS (CHO-NIS12) did not identify additional inhibitory positive samples among those sera that reacted with hNIS in the binding assay. In addition, sera were found to exert similar inhibitory activity on both CHO-NIS9 and CHO-NIS12 cell lines. The failure to find antibodies that inhibit the function of the full-length but not the truncated hNIS is not surprising, as the last 31 amino acids are likely to be intracellular, making this portion of the symporter inaccessible to antibodies in intact cells.
Although a significant correlation was detected between the bioassay and the binding assay, 11 of 22 (50%) sera that inhibited iodide uptake in hNIS-transfected cells did not bind the symporter. This could be due to a number of reasons. First, it is conceivable that the inhibitory activity of some sera is not antibody-mediated, although the results with purified IgGs described here and in our previous study (9) argue against this possibility. Second, some of the inhibition of iodide uptake may result from antibodies that do not act directly on the symporter. Experiments to analyze the effects of hNIS antibody-positive sera on the activity of the Na ϩ /K ϩ ATPase, which is required indirectly for iodide uptake, indicated that the functioning of the sodium ion gradient was not affected by serum samples containing hNIS inhibitory activity. Alternatively, it may be that the in vitrotranslated protein fails to bind these antibodies due to incorrect folding of the molecule, the absence of an abnormal pattern of glycosylation, or may simply reflect differential detection sensitivity in the two assays. This is not unprecedented, as similar findings have been documented for thyroid-stimulating autoantibodies (TSAb). In one study, one third of GD sera positive in the TSH binding inhibiting immunoglobulin assay (TBII) failed to bind in vitro-translated TSH receptor (13) . In another study, using a similar system, none of the TBII-positive sera bound TSH receptor (14) . Moreover, it is clear that TSAb and TBII levels do not cor- relate and some potent TSAb have no detectable TBII activity (24) .
In summary, the present study describes the detection of antibodies in ATD sera that bind the hNIS expressed in a TnT system. About one third of hNIS antibodies were found to bind the symporter without modulating its activity. On the other hand, some hNIS antibodies can only be detected using a bioassay. Overall, we found that 19 of 49 (39%) GD and 10 of 29 (35%) AH sera were positive for hNIS antibodies in at least one of the assays, indicating that the frequency of antibody reactivity against the symporter in GD and AH sera is very similar. The immunoprecipitation assay further offers the possibility of carrying out epitope mapping of the hNIS, which would allow the detailed analysis of this novel thyroid autoantigen, in turn helping to determine the role that NIS autoreactivity plays in the pathogenesis of ATD.
